论文信息 - Clinicopathological Characteristics of RET Rearranged Lung Cancer in European Patients - 字舞流文

Clinicopathological Characteristics of RET Rearranged Lung Cancer in European Patients

L. Bubendorf | R. Hein | W. Engel-Riedel | J. Wolf | R. Büttner | W. Hartmann | C. Grohé | W. Randerath | J. Diebold | S. Krüger | M. Scheffler | H. Schildhaus | S. Rothschild | U. Graeven | L. Heukamp | S. Merkelbach-Bruse | J. Fassunke | L. Nogova | C. Mattonet | W. Schulte | M. Serke | U. Gerigk | A. Schultheis | O. Gautschi | G. Pall | S. Michels | C. Heydt | H. Künstlinger | M. Ihle | A. Draube | H. Lüders | B. Kaminsky | A. Scheel | R. Fischer | F. Aebersold | A. Adams | C. Müller-Naendrup | K. Kambartel | Susanne Schulze-Olden | W. Engel‐Riedel | S. Krüger

[1] T. Zander,et al. Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[2] S. Dhanasekaran,et al. Transcriptome Meta-Analysis of Lung Cancer Reveals Recurrent Aberrations in NRG1 and Hippo Pathway Genes , 2014, Nature Communications.

[3] H. Sakamoto,et al. Alectinib Shows Potent Antitumor Activity against RET-Rearranged Non–Small Cell Lung Cancer , 2014, Molecular Cancer Therapeutics.

[4] I. Plaza-Menacho,et al. Mechanisms of RET signaling in cancer: current and future implications for targeted therapy. , 2014, Cellular signalling.

[5] T. Kohno,et al. RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis , 2014, British Journal of Cancer.

[6] I. Petersen,et al. CD74-NRG1 fusions in lung adenocarcinoma. , 2014, Cancer discovery.

[7] M. Ladanyi,et al. Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. , 2013, Cancer discovery.

[8] S. Aebi,et al. A patient with lung adenocarcinoma and RET fusion treated with vandetanib. , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[9] H. Ji,et al. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10] P. Bunn,et al. Oncogene status predicts patterns of metastatic spread in treatment‐naive nonsmall cell lung cancer , 2012, Cancer.

[11] Yuki Togashi,et al. RET, ROS1 and ALK fusions in lung cancer , 2012, Nature Medicine.

[12] A. Malarcher,et al. Cigarette Smoking Among Adults in the United States , 2008 .

[13] R. Nusse,et al. Illegitimate WNT pathway activation by beta-catenin mutation or autocrine stimulation in T-cell malignancies. , 2008, Cancer research.

[14] M. Santoro,et al. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas , 1990, Cell.